{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:30:07Z","timestamp":1765269007827,"version":"3.40.5"},"reference-count":41,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S0924270824000310_sec31\">\n\t    <jats:title>Objective:<\/jats:title>\n\t    <jats:p>No drugs are currently approved for the treatment of borderline personality disorder (BPD). These studies (a randomised study and its open-label extension) aimed to evaluate the efficacy, safety and tolerability of brexpiprazole for the treatment of BPD.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270824000310_sec32\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>The Phase 2, multicentre, randomised, double-blind, placebo-controlled, parallel-group study enrolled adult outpatients with BPD. After a 1-week placebo run-in, patients were randomised 1:1 to brexpiprazole 2\u20133 mg\/day (flexible dose) or placebo for 11 weeks. The primary endpoint was change in Zanarini Rating Scale for BPD total score from randomisation (Week 1) to Week 10 (timing of randomisation and endpoint blinded to investigators and patients). The Phase 2\/3, multicentre, open-label extension study enrolled patients who completed the randomised study; all patients received brexpiprazole 2\u20133 mg\/day (flexible dose) for 12 weeks. Safety assessments included treatment-emergent adverse events (TEAEs).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270824000310_sec33\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>Brexpiprazole was not statistically significantly different from placebo on the primary endpoint of the randomised study (<jats:italic>N<\/jats:italic> = 324 randomised; <jats:italic>N<\/jats:italic> = 110 analysed per treatment group; least squares mean difference \u22121.02; 95% confidence limits \u22122.75, 0.70; <jats:italic>p<\/jats:italic> = 0.24). Numerical efficacy advantages for brexpiprazole were observed at other time points. The most common TEAE in the randomised study was akathisia (brexpiprazole, 14.0%; placebo, 1.2%); data from the open-label study (<jats:italic>N<\/jats:italic> = 199 analysed) suggested that TEAEs were transient.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270824000310_sec34\">\n\t    <jats:title>Conclusion:<\/jats:title>\n\t    <jats:p>The primary endpoint of the randomised study was not met. Further research on brexpiprazole in BPD is warranted based on possible efficacy signals at other time points and its safety profile.<\/jats:p>\n\t    <jats:p>ClinicalTrials.gov identifiers: NCT04100096, NCT04186403. Funding: Otsuka, Lundbeck.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/neu.2024.31","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T09:27:37Z","timestamp":1732008457000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":2,"title":["A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder"],"prefix":"10.1017","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5780-2559","authenticated-orcid":false,"given":"Brian","family":"Rothman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudette","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Hobart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanco","family":"Hefting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon E.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"S0924270824000310_ref2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"The British Journal of Psychiatry"},{"key":"S0924270824000310_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2015.08.002"},{"key":"S0924270824000310_ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-020-01164-1"},{"volume-title":"User\u2019s Guide for the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD)","year":"2016","author":"First","key":"S0924270824000310_ref10"},{"key":"S0924270824000310_ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-021-00915-y"},{"key":"S0924270824000310_ref11","doi-asserted-by":"publisher","DOI":"10.1186\/2051-6673-1-9"},{"key":"S0924270824000310_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00476-1"},{"key":"S0924270824000310_ref25","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2016.57"},{"volume-title":"Borderline Personality Disorder: Treatment and Management","year":"2009","key":"S0924270824000310_ref26"},{"key":"S0924270824000310_ref27","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"S0924270824000310_ref40","first-page":"75","article-title":"Methodological considerations for treatment trials for persons with borderline personality disorder","volume":"22","author":"Zanarini","year":"2010","journal-title":"Annals of Clinical Psychiatry"},{"key":"S0924270824000310_ref41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.4088\/JCP.08m04138yel","article-title":"A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study","volume":"72","author":"Zanarini","year":"2011","journal-title":"The Journal of Clinical Psychiatry"},{"key":"S0924270824000310_ref1","doi-asserted-by":"publisher","DOI":"10.1521\/pedi_2016_30_269"},{"key":"S0924270824000310_ref20","doi-asserted-by":"publisher","DOI":"10.1037\/per0000453"},{"key":"S0924270824000310_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"S0924270824000310_ref35","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","article-title":"Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase 3, randomized, double-blind study","volume":"76","author":"Thase","year":"2015","journal-title":"The Journal of Clinical Psychiatry"},{"key":"S0924270824000310_ref22","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291722000745"},{"key":"S0924270824000310_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01997-8"},{"key":"S0924270824000310_ref37","doi-asserted-by":"publisher","DOI":"10.1521\/pedi_2012_26_093"},{"key":"S0924270824000310_ref17","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m12058"},{"key":"S0924270824000310_ref9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"The American Journal of Psychiatry"},{"key":"S0924270824000310_ref13","first-page":"1","article-title":"A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder","volume":"220","author":"Grant","year":"2021","journal-title":"The British Journal of Psychiatry"},{"volume-title":"ECDEU Assessment Manual for Psychopharmacology, revised","year":"1976","author":"Guy","key":"S0924270824000310_ref16"},{"key":"S0924270824000310_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.09.009"},{"key":"S0924270824000310_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.37"},{"key":"S0924270824000310_ref8","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000665"},{"key":"S0924270824000310_ref34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09688"},{"key":"S0924270824000310_ref36","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1638913"},{"key":"S0924270824000310_ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13101348"},{"key":"S0924270824000310_ref4","doi-asserted-by":"publisher","DOI":"10.5694\/mja12.10474"},{"key":"S0924270824000310_ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00855-4"},{"key":"S0924270824000310_ref7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","article-title":"Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders","volume":"25","author":"Bridler","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"S0924270824000310_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.01.038"},{"key":"S0924270824000310_ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.3810"},{"key":"S0924270824000310_ref29","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.037903"},{"key":"S0924270824000310_ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40479-019-0106-3"},{"key":"S0924270824000310_ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"S0924270824000310_ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0442-0"},{"key":"S0924270824000310_ref39","doi-asserted-by":"publisher","DOI":"10.1521\/pedi.17.3.233.22147"},{"key":"S0924270824000310_ref18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/03007995.2018.1430220","article-title":"Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study","volume":"34","author":"Hobart","year":"2018","journal-title":"Current Medical Research and Opinion"},{"key":"S0924270824000310_ref24","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.213793"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270824000310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T12:11:32Z","timestamp":1742818292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270824000310\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":41,"alternative-id":["S0924270824000310"],"URL":"https:\/\/doi.org\/10.1017\/neu.2024.31","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"type":"print","value":"0924-2708"},{"type":"electronic","value":"1601-5215"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"\u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e39"}}